Junbao Liu,Chengxu Cui,Lifang Yuan,Jinwan Wang,Shuping Shi,Zhujun Shao,Haijian Tang,Tingting Yang,Chunhui Gao,Nang Wang,Wei Liu. Advanced duodenal carcinoma: Chemotherapy efficacy and analysis of prognostic factors. Oncol Transl Med, 2016, 2: 16-20. |
Advanced duodenal carcinoma: Chemotherapy efficacy and analysis of prognostic factors |
Received:May 03, 2015 Revised:February 01, 2016 |
View Full Text View/Add Comment Download reader |
KeyWord:primary duodenal carcinoma (PDC); palliative chemotherapy; survival; prognostic factors |
Author Name | Affiliation | E-mail | Junbao Liu | Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China | liujb1@sohu.com | Chengxu Cui | Department of Medical Oncology, Cancer Hospital & Institute, Chinese Academy of Medical Sciences & Peking | cuichengxu@csco.org.cn | Lifang Yuan | Department of Medical Oncology, Chaoyang Huanxing Cancer Hospital, Beijing 100122, China | yuanlf122@sohu.com | Jinwan Wang | Department of Medical Oncology, Cancer Hospital & Institute, Chinese Academy of Medical Sciences & Peking | wjw@sohu.com | Shuping Shi | Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China | ssp@sohu.com | Zhujun Shao | Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China | szj@sohu.com | Haijian Tang | Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China | thj@sohu.com | Tingting Yang | Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China | ytt@sohu.com | Chunhui Gao | Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China | gch@sohu.com | Nang Wang | Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China | wn@sohu.com | Wei Liu | Department of Medical Oncology, Chaoyang Sanhuan Cancer Hospital, Beijing 100122, China | lw@sohu.com |
|
Hits: 7981 |
Download times: 10774 |
Abstract: |
Objective: This study aimed to determine the efficacy of chemotherapy and to identify potential chemotherapy agents to treat advanced primary duodenal carcinoma (PDC).
Methods: Seventy-three patients with advanced PDC were included in the study. Response rate (RR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and prognosis were compared among patients using the Cox proportional hazards model.
Results: The overall RR and DCR of 52 patients were 21.15% and 69.23%, respectively. The median PFS and OS times were 4.51 and 11.47 months, respectively. Palliative chemotherapy improved the OS of patients with advanced PDC compared with patients who did not receive chemotherapy (14.28 months vs. 5.20 months, HR = 0.205, 95% CI: 0.077 to 0.547, P = 0.0016). Multivariate analysis indicated mucinous histology and liver metastasis as factors predictive of poor prognosis in patients with advanced PDC.
Conclusion: Palliative chemotherapy may improve the OS of patients with advanced PDC. Mucinous histology and liver metastasis were the main prognostic factors in patients with advanced PDC. |
Close |
|
|
|